GR1005016B - IgG & IgY ANTIBODIES DEVELOPED VERSUS THE HUMANIN SPECIALLY-SYNTHESIZED EPITOPE DERIVATIVE (BIO-ACTIVE 24-PEPTIDE) RELATED TO THE ALZHEIMER' S DISEASE AND DETECTION OF SAID BIO-ACTIVE 24- PEPTIDE BYSAME ANTIBODIES - Google Patents
IgG & IgY ANTIBODIES DEVELOPED VERSUS THE HUMANIN SPECIALLY-SYNTHESIZED EPITOPE DERIVATIVE (BIO-ACTIVE 24-PEPTIDE) RELATED TO THE ALZHEIMER' S DISEASE AND DETECTION OF SAID BIO-ACTIVE 24- PEPTIDE BYSAME ANTIBODIESInfo
- Publication number
- GR1005016B GR1005016B GR20040100187A GR2004100187A GR1005016B GR 1005016 B GR1005016 B GR 1005016B GR 20040100187 A GR20040100187 A GR 20040100187A GR 2004100187 A GR2004100187 A GR 2004100187A GR 1005016 B GR1005016 B GR 1005016B
- Authority
- GR
- Greece
- Prior art keywords
- peptide
- antibodies
- derivative
- humanin
- epitope
- Prior art date
Links
- DPEUWKZJZIPZKE-OFANTOPUSA-N 330936-69-1 Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)CCSC)C1=CC=CC=C1 DPEUWKZJZIPZKE-OFANTOPUSA-N 0.000 title abstract 12
- 101000988651 Homo sapiens Humanin-like 1 Proteins 0.000 title abstract 11
- 102000011854 humanin Human genes 0.000 title abstract 11
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 230000000975 bioactive effect Effects 0.000 title 2
- 238000001514 detection method Methods 0.000 title 1
- 102000015636 Oligopeptides Human genes 0.000 abstract 3
- 108010038807 Oligopeptides Proteins 0.000 abstract 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- 239000004472 Lysine Substances 0.000 abstract 2
- 238000002649 immunization Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 241000287828 Gallus gallus Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000021736 acetylation Effects 0.000 abstract 1
- 238000006640 acetylation reaction Methods 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000013345 egg yolk Nutrition 0.000 abstract 1
- 210000002969 egg yolk Anatomy 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 238000011587 new zealand white rabbit Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000007790 solid phase Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
0040100187The present invention relates to the development and isolation of anti-bodies (IgG, IgY) recognizing the 24-peptide of humanin (HN) related to the Alzheimer's disease. These anti-bodies have been developed in the New Zealand white rabbits or in chicken IgY, and isolated, in gram quantities from egg yolks, through the application of a new improved methodology versus the special synthesized epitope derivative of the humanin (Lys-Asp-Leu-Pro-Val-Lys(Nac)-Arg-Arg-Ala)previously coupledto an adequate immune carrier (e.g. protein of great molecular weight) indispensable for the actuation of the immunisation system of the experiment animals. The humanin epitope derivative, which is synthetically prepared with the Fmoc-method consisting in the solid phase peptides synthesis, is composed of the oligopeptide segment 17-24 of the carboxytelic terminal of the HN molecule. Unlike the hydrophobic whole 24-peptide, the oligopeptide segment is hydrophylic, and provides proper protectionto the lysine -NH2 (see acetylation) encountered at the position 21 of the natural HN sequence; the amino-acid lysine -not existing in the natural peptide sequence and being used for the coupling of the epitope derivative with the immune carrier - is incorporated to the N-terminal of said oligopeptide segment. After evaluation carried out by immunization recording and enzyme-immuno-analysis methods, it has been found that the antibodies developed versus the HN epitope derivative recognize the HN with higher chemical avidity than that used by antibodies-witness developed versus the whole 24-peptide coupled with the same immune carrier, while the IgY antibodies have shown greater avidity for the HN than the corresponding IgG antibodies. Theaforementioned antibodies may be used in a plurality of in vitro applications. Furthermore, the special HN synthesized epitope derivative can be used in the preparation of synthesized vaccines against diseases possibly showing high in vivo humanin co
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20040100187A GR1005016B (en) | 2004-05-14 | 2004-05-14 | IgG & IgY ANTIBODIES DEVELOPED VERSUS THE HUMANIN SPECIALLY-SYNTHESIZED EPITOPE DERIVATIVE (BIO-ACTIVE 24-PEPTIDE) RELATED TO THE ALZHEIMER' S DISEASE AND DETECTION OF SAID BIO-ACTIVE 24- PEPTIDE BYSAME ANTIBODIES |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20040100187A GR1005016B (en) | 2004-05-14 | 2004-05-14 | IgG & IgY ANTIBODIES DEVELOPED VERSUS THE HUMANIN SPECIALLY-SYNTHESIZED EPITOPE DERIVATIVE (BIO-ACTIVE 24-PEPTIDE) RELATED TO THE ALZHEIMER' S DISEASE AND DETECTION OF SAID BIO-ACTIVE 24- PEPTIDE BYSAME ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR1005016B true GR1005016B (en) | 2005-10-11 |
Family
ID=35445916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20040100187A GR1005016B (en) | 2004-05-14 | 2004-05-14 | IgG & IgY ANTIBODIES DEVELOPED VERSUS THE HUMANIN SPECIALLY-SYNTHESIZED EPITOPE DERIVATIVE (BIO-ACTIVE 24-PEPTIDE) RELATED TO THE ALZHEIMER' S DISEASE AND DETECTION OF SAID BIO-ACTIVE 24- PEPTIDE BYSAME ANTIBODIES |
Country Status (1)
| Country | Link |
|---|---|
| GR (1) | GR1005016B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8497072B2 (en) | 2005-11-30 | 2013-07-30 | Abbott Laboratories | Amyloid-beta globulomer antibodies |
| US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
| US8877190B2 (en) | 2006-11-30 | 2014-11-04 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| US9176150B2 (en) | 2003-01-31 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
-
2004
- 2004-05-14 GR GR20040100187A patent/GR1005016B/en unknown
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10464976B2 (en) | 2003-01-31 | 2019-11-05 | AbbVie Deutschland GmbH & Co. KG | Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
| US9176150B2 (en) | 2003-01-31 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
| US8497072B2 (en) | 2005-11-30 | 2013-07-30 | Abbott Laboratories | Amyloid-beta globulomer antibodies |
| US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
| US10538581B2 (en) | 2005-11-30 | 2020-01-21 | Abbvie Inc. | Anti-Aβ globulomer 4D10 antibodies |
| US10323084B2 (en) | 2005-11-30 | 2019-06-18 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
| US10208109B2 (en) | 2005-11-30 | 2019-02-19 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
| US9540432B2 (en) | 2005-11-30 | 2017-01-10 | AbbVie Deutschland GmbH & Co. KG | Anti-Aβ globulomer 7C6 antibodies |
| US9394360B2 (en) | 2006-11-30 | 2016-07-19 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
| US9359430B2 (en) | 2006-11-30 | 2016-06-07 | Abbvie Inc. | Abeta conformer selective anti-Abeta globulomer monoclonal antibodies |
| US9951125B2 (en) | 2006-11-30 | 2018-04-24 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
| US8877190B2 (en) | 2006-11-30 | 2014-11-04 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| US10047121B2 (en) | 2010-08-14 | 2018-08-14 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8859209B2 (en) | Reimmunization and antibody design | |
| EP2027158B1 (en) | Method for immunizing an avian species | |
| JP4272535B2 (en) | Antibodies with T cell receptor-like specificity and higher affinity and their use in the detection and treatment of cancer, viral infections, and autoimmune diseases | |
| NO20045021L (en) | Immunological methods and preparations for the treatment of Alzheimer's disease | |
| Hashiguchi et al. | Immunological basis of M13 phage vaccine: Regulation under MyD88 and TLR9 signaling | |
| KR20120084298A (en) | Peptide clearing agents | |
| GR1005016B (en) | IgG & IgY ANTIBODIES DEVELOPED VERSUS THE HUMANIN SPECIALLY-SYNTHESIZED EPITOPE DERIVATIVE (BIO-ACTIVE 24-PEPTIDE) RELATED TO THE ALZHEIMER' S DISEASE AND DETECTION OF SAID BIO-ACTIVE 24- PEPTIDE BYSAME ANTIBODIES | |
| JP4705694B2 (en) | Peptides with immunoglobulin binding ability | |
| Lu et al. | A de novo designed template for generating conformation-specific antibodies that recognize α-helices in proteins | |
| Walczak et al. | Method for generation of peptide‐specific igy antibodies directed to Staphylococcus aureus extracellular fibrinogen binding protein epitope | |
| Beck et al. | Peptides as tools and drugs for immunotherapies | |
| US20060057636A1 (en) | Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins | |
| Joisson et al. | Antigenic analysis of bean pod mottle virus using linear and cyclized synthetic peptides | |
| Dunn et al. | Fine mapping of the binding sites of monoclonal antibodies raised against the Pk tag | |
| Uray et al. | Peptide epitopes: identification and structural modifications of synthetic antigens | |
| Kaur et al. | Immunological implications of structural mimicry between a dodecapeptide and a carbohydrate moiety | |
| Böttger et al. | Identification of peptide mimotopes for the fluorescein hapten binding of monoclonal antibody B13‐DE1 | |
| Lou et al. | A Lewisy epitope mimicking peptide induces anti‐Lewisy immune responses in rabbits and mice | |
| AU2951392A (en) | Peptides and antibodies for treatment of rheumatoid arthritis | |
| US5837686A (en) | Peptides and antibodies for treatment of rheumatoid arthritis | |
| Saiki et al. | Induction of humoral responses specific for paraneoplastic cerebellar degeneration-associated antigen by whole recombinant yeast immunization | |
| Subramanian et al. | Immunological relatedness of chicken and human riboflavin carrier protein | |
| EP4624487A1 (en) | Production of antibodies against protein | |
| Koshy et al. | Antigenic determinants at the carboxy terminus of chicken egg white riboflavin carrier protein (RCP): epitope mapping and antibody-mediated pregnancy curtailment in rodents | |
| Uray et al. | Effect of D-amino acid substitution in a mucin 2 epitope on mucin-specific monoclonal antibody recognition |